Cerity Partners LLC Fate Therapeutics Inc Transaction History

Cerity Partners LLC

  • $44.7 Billion
  • Q3 2024

A detailed history of Cerity Partners LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Cerity Partners LLC holds 16,288 shares of FATE stock, worth $37,299. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,288
Previous 16,016 1.7%
Holding current value
$37,299
Previous $52,000 9.62%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
BUY
$3.12 - $5.57 $848 - $1,515
272 Added 1.7%
16,288 $57,000
Q2 2024

Aug 13, 2024
SELL
$3.26 - $7.08 $2,575 - $5,593
-790 Reduced 4.7%
16,016 $52,000
Q1 2024

May 14, 2024
SELL
$3.54 - $8.35 $54,402 - $128,322
-15,368 Reduced 47.77%
16,806 $123,000
Q4 2023

Jan 26, 2024
BUY
$1.65 - $3.94 $53,087 - $126,765
32,174 New
32,174 $120,000
Q2 2023

Aug 14, 2023
BUY
$4.76 - $6.59 $152,082 - $210,550
31,950 New
31,950 $152,000
Q1 2020

May 14, 2020
SELL
$17.28 - $31.88 $174,009 - $321,031
-10,070 Closed
0 $0
Q4 2019

Feb 14, 2020
BUY
$13.39 - $20.73 $134,837 - $208,751
10,070 New
10,070 $197,000
Q3 2018

Nov 15, 2018
SELL
$8.75 - $16.29 $121,800 - $226,756
-13,920 Closed
0 $0
Q1 2018

May 15, 2018
BUY
$6.3 - $13.77 $87,696 - $191,678
13,920 New
13,920 $136,000
Q4 2017

Feb 14, 2018
SELL
$3.94 - $6.64 $54,844 - $92,428
-13,920 Closed
0 $0
Q3 2017

Nov 13, 2017
BUY
$2.6 - $4.31 $36,192 - $59,995
13,920
13,920 $55,000

Others Institutions Holding FATE

# of Institutions
175
Shares Held
115M
Call Options Held
53.7K
Put Options Held
9K
View Full List

About FATE THERAPEUTICS INC

FATE Quotes by TradingView
  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $222M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Cerity Partners LLC Portfolio

Follow Cerity Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cerity Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cerity Partners LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email